Vernalis gets another CRL in cough and cold pipeline

Vernalis plc (LSE:VER) lost 2p (11%) to 17p Monday after it said FDA issued a complete response letter to an NDA for CCP-08 to treat cough and cold. The letter follows a CRL issued in April for its other cough and cold candidate CCP-07 (see BioCentury Extra, April 21).

Vernalis said the CRL for CCP-08 "indicated that the outstanding items which resulted in the CRL for CCP-07 remain and that they need to be addressed prior to the resubmission and approval of both NDAs." The company did not respond to inquiries regarding the content of the letters...